Amanda Gillespie-Twardy, MD
Hematology & Oncology · Roanoke, VANPI 1417140559
Payments from drug & device makers
Across 2,707 payments — averaging $4504.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Beigene, Ltd.$5.5M
- Genentech, Inc.$1.2M
- Seagen Inc.$1M
- AstraZeneca$837K
- Eli Lilly$799K
- Beone Medicines Ltd.$377K
- plus $2.5M from 23 others
Across 5 payments — averaging $3296.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$15K
- Pfizer$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Beigene, Ltd. | 291 | $5,469,531 |
| Genentech, Inc. | 514 | $1,169,361 |
| Seagen Inc. | 860 | $1,035,835 |
| AstraZeneca | 41 | $836,804 |
| Eli Lilly | 27 | $798,999 |
| Beone Medicines Ltd. | 14 | $376,841 |
| Epizyme, Inc. | 169 | $333,240 |
| Amgen | 12 | $313,904 |
| Bristol Myers Squibb | 8 | $310,593 |
| Pfizer | 279 | $284,264 |
| E.r. Squibb & Sons, L.L.C. | 10 | $223,062 |
| Takeda Pharmaceuticals U.S.A., Inc. | 64 | $210,322 |
| Merck | 35 | $172,885 |
| Morphosys AG | 145 | $124,554 |
| AbbVie | 13 | $117,096 |
| Incyte Corporation | 111 | $105,805 |
| Regeneron | 52 | $101,312 |
| Jazz Pharmaceuticals Inc. | 25 | $64,100 |
| Astrazeneca UK Limited | 8 | $40,463 |
| Acerta Pharma LLC | 6 | $40,095 |
| F. Hoffmann-la Roche AG | 5 | $34,805 |
| GSK | 7 | $23,449 |
| Veru Inc. | 4 | $3,900 |
| Morphosys, US Inc. | 1 | $956 |
| Tactile Systems Technology Inc | 2 | $73 |
| Genentech USA, Inc. | 1 | $53 |
| Puma Biotechnology, Inc. | 1 | $23 |
| Gilead | 1 | $12 |
| Exelixis Inc. | 1 | $12 |
How this compares
$12,192,350 in reported general payments places this provider in the 95th percentile of 293 hematology & oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Roanoke
- Mark KochenderferRoanoke$8.6M
- Donald VileRoanoke$1.2M
- Craig PortellCharlottesville$12.9M
- Sekwon JangFairfax$11.8M
- Mark FlemingHampton$10M
- Mitul GandhiManassas$6.9M
- Michael DansoNorfolk$6.9M
- Jerome GoldschmidtChristiansburg$6.5M
- William IrvinMidlothian$4.3M
- Lakshminarayanan NandagopalFredericksburg$3.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.